This content is from: Patents

USPTO issues memorandum in response to CellzDirect and Sequenom

The USPTO tells examiners the Federal Circuit’s CellzDirect ruling “highlighted several important points” but says its subject matter eligibility guidance and training examples are already consistent with it

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.

REQUEST ACCESS

Are you already an Managing IP subscriber? Login here

Related

Instant access to all of our content. Membership Options | One Week Trial